New Antibody-Drug conjugate targets Hard-to-Treat cancers
NCT ID NCT06465069
First seen Nov 01, 2025 · Last updated Jun 21, 2026 · Updated 36 times
Summary
This early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and others. The goal is to find a safe dose and see if the drug can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aichi Cancer Center Hospital
RECRUITINGNagoya, 464-8681, Japan
-
Asan Medical Center
RECRUITINGSeoul, 05505, South Korea
-
Beijing Cancer hospital
RECRUITINGBeijing, 100142, China
-
Catalan Institute of Oncology Duran i Reynals Hospital
RECRUITINGBarcelona, 8908, Spain
-
City of Hope National Medical Center
RECRUITINGDuarte, California, 91010-0269, United States
-
Columbia University Irving Medical Center
RECRUITINGNew York, New York, 10032-3729, United States
-
Florida Cancer Specialists and Research Institute
COMPLETEDSt. Petersburg, Florida, 33705, United States
-
Hospital Madrid Norte Sanchinarro
RECRUITINGMadrid, 28050, Spain
-
Hospital Universitario 12 de Octubre
RECRUITINGMadrid, 28041, Spain
-
Hospital Universitario Virgen Del Rocio
RECRUITINGSeville, 41013, Spain
-
IU Simon Cancer Center
RECRUITINGIndianapolis, Indiana, 46202, United States
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029-6574, United States
-
Institut Gustave Roussy (Igr)
RECRUITINGVillejuif, 94805, France
-
Linear Clinical Research
RECRUITINGNedlands, 6009, Australia
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02215, United States
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
-
National Cancer Center Hospital
NOT_YET_RECRUITINGChūōku, 104-0045, Japan
-
National Cancer Center Hospital East
RECRUITINGKashiwa, Chiba, 277-8577, Japan
-
Renji Hospital, Shanghai Jiaotong University School of Medicine
RECRUITINGShanghai, 200000, China
-
START Midwest Cancer and Hematology Centers of W Michigan
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
START Mountain Region
RECRUITINGWest Valley City, Utah, 84119, United States
-
Sarah Cannon Research Institute
RECRUITINGNashville, Tennessee, 37203, United States
-
Sarah Cannon Research Institute at HealthOne
RECRUITINGDenver, Colorado, 80218, United States
-
South Texas Accelerated Research Therapeutics (START)
RECRUITINGSan Antonio, Texas, 78229, United States
-
St Bartholomew's Hospital
RECRUITINGLondon, EC1A 7BE, United Kingdom
-
St Vincent's Hospital
RECRUITINGDarlinghurst, 2010, Australia
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, 510060, China
-
The Cancer Institute Hospital of JFCR
RECRUITINGKōtō City, 135-8550, Japan
-
The Christie NHS Foundation Trust
RECRUITINGManchester, M20 4BX, United Kingdom
-
UCLA Department of Medicine-Hematology/Oncology
RECRUITINGLos Angeles, California, 90024, United States
-
University of Chicago Hospital
RECRUITINGChicago, Illinois, 60637, United States
-
University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030-4000, United States
-
University of Utah - Huntsman Cancer Institute
RECRUITINGSalt Lake City, Utah, 84112, United States
-
Washington University School of Medicine in St. Louis
RECRUITINGSt Louis, Missouri, 63110, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LY4052031 (an antibody-drug conjugate targeting Nectin-4)
What this could lead to
If successful, this could lead to a new treatment option for several advanced cancers that are hard to treat.
What could go wrong
This is an early Phase 1 trial, so the drug may not be effective or could have serious side effects. It will take years to know if it works.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.